Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction-Reference-Cited by-同舟云学术

Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction

Published:1995-05-25 Issue:21 Volume:332 Page:1418-1424
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Mark Daniel B.,Hlatky Mark A.,Califf Robert M.,Naylor C. David,Lee Kerry L.,Armstrong Paul W.,Barbash Gabriel,White Harvey,Simoons Maarten L.,Nelson Charlotte L.,Clapp-Channing Nancy,Knight J. David,Harrell Frank E.,Simes John,Topol Eric J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJM199505253322106

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Shedding light on the “smoker's paradox”;Cardiovascular Revascularization Medicine;2024-07

2. A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Streptokinase in the Management of Myocardial Infarction in Developing Countries;Cureus;2023-08-25

3. Point estimation for adaptive trial designs II: Practical considerations and guidance;Statistics in Medicine;2023-04-05

4. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand;LANCET REG HEALTH-W;2022

5. Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand;The Lancet Regional Health - Western Pacific;2022-09